VYNE — Vyne Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual balance sheet for Vyne Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	C2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Cash and Short Term Investments	57.6	42.3	30.9	30.6	19.9
Net Total Accounts Receivable
Net Total Receivables	15.8	7.58	5.17	0	—
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	87.3	63.2	38.3	96	64.4
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	2.14	0.354	0	0.207	0.206
Other Long Term Assets
Total Assets	93.7	67	40.8	97.7	66.9
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	21.8	18.4	9.35	7.54	14.8
Long Term Debt
Total Long Term Debt
Total Debt
Minority Interest
Total Other Liabilities
Total Liabilities	56.2	18.4	9.35	8.95	14.8
Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Unrealized Gain / Loss
Total Equity	37.5	48.6	31.4	88.7	52.1
Total Liabilities & Shareholders' Equity	93.7	67	40.8	97.7	66.9
Total Common Shares Outstanding
Total Preferred Shares Outstanding